Novartis backs FY17 revenue guidance of 'broadly in line with the prior year'
Novartis provided the following FY17 outlook: "We re-confirm our Group outlook as presented at the beginning of 2017. Group net sales in 2017 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition, including the continued genericization of Gleevec/Glivec in the U.S. and Europe. From a divisional perspective, we expect net sales performance in 2017 to be as follows: Innovative Medicines: broadly in line with prior year, to a slight increase; Sandoz: broadly in line with prior year; Alcon: revised upward to low single digit growth. Group core operating income in 2017 is expected to be broadly in line with prior year to a low single digit decline. If mid-July exchange rates prevail for the remainder of 2017, the currency impact for the year would be negative 1 percentage point on net sales and negative 2 percentage points on core operating income."